Our Product

About Coxor™
Click here only if you are Healthcare Personnel

Rapid onset of action

Coxor™ is a powder and solvent for oral solution for emergency treatment for suspected acute myocardial infarction. This medicine is used in adults above 18 years for suspected acute myocardial infarction (heart attack) after contact with emergency medical services.

In case of symptoms of a suspected acute myocardial infarction, the patient should call the national rescue number as soon as possible. If advised to do so by the emergency medical services, 300 mg of Coxor™ should be taken as quickly as possible.

The content is to be drunk following reconstitution. The powder is to be dissolved in the solvent and shaken until it is dissolved.

Medicinal product not subject to medical prescription



 Product characteristics (link)
Design
Coxor is designed to be ready-to-use and simple to self-administer for at-risk patient groups.
Production
Asamedic started production of the drug in the fall of 2018 and set 6,000 vials in stability program. Full scale production started november 2020.
DCP
DCP well-established use application was submitted in December 2019, with Norway as RMS and Denmark as CMS.
Positive outcome
End of procedure with a positive outcome took place in January 2021.
Product offering
The use of acetylsalicylic acid as self-medication for heart attacks is not currently widely promoted, even though its use is advised by the expert community. Coxor™ will be the first liquid of its kind to be marketed for this purpose alone

“In a critical situation, ASA should be provided in a solution with rapid onset of action.”
Wollard et al, «Life saving early and immediate aspirin: too little too late»

"After five minutes, the level of ASA in the blood is 15x larger with a fluid than with a tablet.”
Muir et al, «The influence of dosing form on aspirin kinetics: implications for acute cardiovascular use»

"ASA administered alone quickly after chest pain begins reduces mortality in heart attack by 23%.”
ISIS-2 (Second International Study of lnfarct Survival) Collaborative Group (1988) 5)
Coxor™ enables immediate intake of acetylsalicylic acid
1

When administered orally, acetylsalicylic acid is very rapidly absorbed. Following single dose oral administration to healthy volunteers in four different formulations (600 mg soluble tablets, 600 mg dispersible tablets, 650 mg plain tablets and 500 mg enteric-coated granules), acetylsalicylic acid was absorbed more rapidly from soluble tablets and mouth-dispersible tablets.
2

Coxor™ enables immediate intake of acetylsalicylic acid without needing a glass of water and does not depend on the patient’s saliva production.

3

Coxor™ is the first dedicated emergency OTC approved product against heart attack with appropriate user properties.

Highlights

Positive results

Positive results on 18 months stability study, voluntary clinical trial completed. Favorable study results expected to be published H1 2022.

Secure patent protection

Extensive investment projects and studies performed to secure patent protection — patent approved in Europe, Australia, India and several other countries. Patent pending in numerous jurisdictions throughout the world.

ISCHAEMIC HEART DISEASE
Leading cause

The world’s biggest killer is ischaemic heart disease, responsible for 16% of the world’s total deaths. Since 2000, the largest increase in deaths has been for this disease, rising by more than 2 million to 8.9 million deaths in 2019.

15 people die every minute

from a heart attack (that’s 4 times more lives than Covid-19 has taken in the past year). In the US alone a person has a heart attack every 40 seconds. Studies show that prolonged delays often occur before inhospital therapy , and that prehospital treatment with the appropriate drug could save lives and reduce after-effects.
WHO, 2020. Read 02.15.2021